Edition:
India

Abcam PLC (ABCA.L)

ABCA.L on London Stock Exchange

1,245.00GBp
18 Sep 2020
Change (% chg)

3.00 (+0.24%)
Prev Close
1,242.00
Open
1,277.00
Day's High
1,277.00
Day's Low
1,238.00
Volume
284,876
Avg. Vol
443,098
52-wk High
1,584.00
52-wk Low
943.00

Latest Key Developments (Source: Significant Developments)

Abcam FY Reported Oper Profit 10.5 Mln Stg
Monday, 14 Sep 2020 

Sept 14 (Reuters) - Abcam PLC ::FY REVENUE 260 MILLION STG VERSUS 259.9 MILLION STG YEAR AGO.FY REPORTED OPERATING PROFIT OF £10.5M (2018/19: £56.1M).DIVIDENDS OF £25M DISTRIBUTED TO SHAREHOLDERS DURING YEAR.COMPANY IS NOT PROVIDING FULL YEAR GUIDANCE AT THIS TIME.  Full Article

Abcam Agreed To Raise £110.0 Mln Of Equity Capital
Thursday, 9 Apr 2020 

April 9 (Reuters) - Abcam PLC ::HAS AGREED TO RAISE £110.0 MILLION OF EQUITY CAPITAL THROUGH ISSUANCE OF 10.0 MILLION NEW ORDINARY SHARES OF 0.2 PENCE EACH.ISSUANCE OF SHARES REPRESENTING 4.85 PER CENT OF EXISTING ISSUED SHARE CAPITAL OF COMPANY.ISSUANCE OF SHARES O DURABLE CAPITAL PARTNERS LP AT AN ISSUE PRICE OF 1,100 PENCE PER SHARE.  Full Article

Abcam Plc Posts HY Profit Before Tax Of 26 Mln STG
Monday, 9 Mar 2020 

March 9 (Reuters) - Abcam PLC ::H1 REVENUE ROSE 10.8 PERCENT TO 138.2 MILLION STG.C.£3M REVENUE REDUCTION TO DATE DUE TO COVID-19, PREDOMINANTLY ORIGINATING FROM EARLY SPREAD OF VIRUS IN CHINA.BROADER CHINA ACTIVITY RETURNING, ALBEIT STILL BELOW FULL LEVELS PRIOR TO OUTBREAK.HY REPORTED REVENUE 138.2 MILLION STG VERSUS 124.7 MILLION STG.HY REPORTED PROFIT BEFORE TAX 26.0 MILLION STG VERSUS 33.7 MILLION STG.HY ADJUSTED PBT 32.8 MILLION STG VERSUS 41.1 MILLION STG.INTERIM DIVIDEND OF 3.55 PENCE PER SHARE.  Full Article

Abcam Plc Announces Acquisition Of Marker Gene Technologies
Wednesday, 4 Mar 2020 

March 4 (Reuters) - Abcam Plc ::ABCAM PLC - ACQUISITION OF MARKER GENE TECHNOLOGIES.ABCAM PLC - FINANCIAL TERMS OF ACQUISITION HAVE NOT BEEN DISCLOSED.ABCAM PLC - PROPOSED DEAL EXPECTED TO HAVE A MINIMAL IMPACT ON REVENUE AND EARNINGS IN CURRENT FINANCIAL YEAR.ABCAM PLC - A SUBSTANTIAL PORTION OF CONSIDERATION FOR ACQUISITION WILL BE FUNDED FROM NEWLY ISSUED ABCAM SHARES.  Full Article

Adaptimmune Announces Appointment Of Gavin Wood As CFO
Tuesday, 18 Feb 2020 

Feb 18 (Reuters) - Adaptimmune Therapeutics PLC ::ADAPTIMMUNE ANNOUNCES APPOINTMENT OF GAVIN WOOD AS CHIEF FINANCIAL OFFICER.ADAPTIMMUNE THERAPEUTICS PLC - MICHAEL GARONE, WHO IS SERVING AS INTERIM CFO, WILL STEP DOWN ON MARCH 31, 2020.ADAPTIMMUNE THERAPEUTICS PLC - GAVIN WOOD MOST RECENTLY SERVED AS CFO AND A DIRECTOR OF ABCAM PLC.  Full Article

Abcam Expands Cell Engineering Capabilities
Thursday, 30 Jan 2020 

Jan 30 (Reuters) - Abcam PLC ::ABCAM PLC - ABCAM EXPANDS CELL ENGINEERING CAPABILITIES.ABCAM PLC - ABCAM EXPANDS CELL ENGINEERING CAPABILITIES.ABCAM PLC - EXPANDS CELL ENGINEERING CAPABILITIES VIA ASSET PURCHASE OF APPLIED STEMCELL'S GENE EDITING PLATFORM AND ONCOLOGY PRODUCT PORTFOLIO.ABCAM PLC - FINANCIAL TERMS OF TRANSACTION HAVE NOT BEEN DISCLOSED.ABCAM PLC - TRANSACTION EXPECTED TO HAVE A MINIMAL IMPACT ON REVENUE AND EARNINGS IN CURRENT FINANCIAL YEAR.  Full Article

Abcam Appoints Michael Baldock As CFO
Tuesday, 14 Jan 2020 

Jan 14 (Reuters) - Abcam PLC ::ABCAM PLC - APPOINTMENT OF CHIEF FINANCIAL OFFICER.ABCAM PLC - APPOINTMENT OF MICHAEL BALDOCK AS CHIEF FINANCIAL OFFICER WITH EFFECT FROM 3 FEBRUARY 2020.ABCAM PLC - MICHAEL BALDOCK ASSUMES ROLE OF CHIEF FINANCIAL OFFICER FROM GAVIN WOOD.  Full Article

Abcam Sees Higher HY Rev; FY Adj. EBIT Margin Towards Lower End Of View
Friday, 10 Jan 2020 

Jan 10 (Reuters) - Abcam PLC ::EXPECTS TO REPORT TOTAL FIRST HALF REVENUE OF £138.2 MILLION (H1 2019: £124.7 MILLION).TIGHTENING CONSTANT CURRENCY REVENUE GROWTH TARGET FOR FULL YEAR TO 9-10%.ADJUSTED OPERATING PROFIT MARGIN IS EXPECTED TO BE TOWARDS LOWER END OF GUIDANCE OF 25-28% FOR FULL YEAR.EXPECTS GROSS MARGIN TO BE BROADLY IN LINE WITH FIRST HALF OF LAST YEAR (H1 2019: 70.2%).  Full Article

Abcam Says Transaction Complete Between Abcam And Expedeon
Thursday, 2 Jan 2020 

Jan 2 (Reuters) - Abcam PLC ::TRANSACTION COMPLETE BETWEEN ABCAM AND EXPEDEON.TRANSACTION TO ACQUIRE EXPEDEON LTD, INNOVA BIOSCIENCES LTD AND TGR BIOSCIENCES FROM EXPEDEON AG HAS NOW COMPLETED.  Full Article

Expedeon And Abcam Close Transaction Of EUR 120 Mln
Thursday, 2 Jan 2020 

Jan 2 (Reuters) - EXPEDEON AG ::EXPEDEON AG AND ABCAM PLC CLOSE EUR 120 MILLION TRANSACTION.EXPEDEON AG PLANS NAME CHANGE TO 4BASEBIO AG AND CHANGE OF TICKER TO 4BSB.EUR 105.6 MILLION IS DUE IMMEDIATELY AND EUR 14.4 MILLION WILL BE HELD IN ESCROW FOR TWO YEARS.COMPANY'S SHARES WILL CONTINUE TO BE LISTED ON FRANKFURT STOCK EXCHANGE AND GERMAN SECURITIES IDENTIFICATION CODE (WKN) WILL REMAIN UNCHANGED.  Full Article

BRIEF-Abcam Says Milner Will Not Stand For Re-Election As Non-Executive Deputy Chairman

* ABCAM PLC - JONATHAN MILNER, CO-FOUNDER AND NON-EXECUTIVE DEPUTY CHAIRMAN OF ABCAM, HAS INFORMED BOARD THAT HE WILL NOT STAND FOR RE-ELECTION Source text for Eikon: Further company coverage: